NCT06235775 - Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG

GV1001 Placebo

0.9% normal saline

DRUG

GV1001 1.12mg

Lyophilized peptide from hTERT

Trial Locations (5)

Seoul National University Bundang Hospital, Seongnam-si

Kyung Hee University Hospital, Seoul

Samsung Medical Center, Seoul

Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul

Seoul National University Hospital, Seoul